NF-κB and COX-2 expression in nonmalignant endometrial lesions and cancer

American Journal of Clinical Pathology

Volumn 141, Issue 2, 2014, Pages 196-203

  Faloppa, Carlos Chaves ^a   Baiocchi, Glauco ^a   Cunha, Isabela Werneck ^a   Fregnani, José Humberto Tavares Guerreiro ^b   Osorio, Cynthia Aparecida Bueno Toledo ^a   Fukazawa, ElzaMieko ^a   Kumagai, LillianYuri ^a   Badiglian Filho, Levon ^a   Pinto, Gabriel Lowndes Souza ^c   Soares, Fernando Augusto ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

^c Department of Clinical Oncologyc   (Brazil)

Author keywords

Carcinogenesis; Cyclooxygenase 2; Endometrial cancer; Endometrial hyperplasia; Nuclear factor B; Prognostic factor

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA; ENDOMETRIOID ENDOMETRIAL CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CARCINOGENESIS; CARCINOMA IN SITU; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUCLEAR FACTOR-ΚB; PATHOLOGY; POLYP; PROGNOSIS; PROGNOSTIC FACTOR; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

CARCINOGENESIS; CYCLOOXYGENASE 2; ENDOMETRIAL CANCER; ENDOMETRIAL HYPERPLASIA; NUCLEAR FACTOR-ΚB; PROGNOSTIC FACTOR;

CARCINOMA IN SITU; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NF-KAPPA B; POLYPS; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84895174893     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPV7U7PGHOWEQG     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Wright JD, Barrena Medel NI, et al. Contemporary management of endometrial cancer. Lancet. 2012;379:1352-1360.
3. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791. (Pubitemid 46630943)
4. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16:8-13.
5. Kurman RJ, McConnell TG. Characterization and comparison of precursors of ovarian and endometrial carcinoma: parts I and II. Int J Surg Pathol. 2010;18:181s-189s.
6. Nieminen TT, Gylling A, Abdel-Rahman WM, et al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res. 2009;15:5772-5783.
7. Wang D, Dubois N. Eicosanoids and cancer. Nature Rev Cancer. 2010;10:181-193.
8. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466. (Pubitemid 39329586)
9. Chaturvedi MM, Sung B, Yadav VR, et al. NF-κB addiction and its role in cancer: "one size does not fit all." Oncogene. 2011;30:1615-1630.
10. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signaling complex. Oncogene. 1999;18:6013-6020. (Pubitemid 29535013)
11. Hirano S, Furutama D, Hanafusa T. Physiologically high concentrations of 17β-estradiol enhance NF-κB activity in human T cells. Am J Physiol Regul Integr Comp Physiol. 2007;292:1465-1471.
12. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002;68-69:95-114. (Pubitemid 35247390)
13. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96-102. (Pubitemid 36135884)
14. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441:431-436. (Pubitemid 44050137)
15. Mutter GL, for the Endometrial Collaborative Group. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? Gynecol Oncol. 2000;76:287-290.
16. Ghosh N, Chaki R, Mandal V, et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62:233-244.
17. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93:705-716 [erratum in: Cell. 1998; 94:271]. (Pubitemid 28257578)
18. Ali-Fehmi R, Che M, Khalifeh I, et al. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer. 2003;98:1423-1429. (Pubitemid 37151497)
19. Davies G, Salter J, Hills M, et al. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003;9:2651-2656. (Pubitemid 36842109)
20. Joo YE, Rew JS, Seo YH, et al. Cydooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003;37:28-33.
21. Buchholz TA, Garg AK, Chakravarti N, et al. The nuclear transcription factor κB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005;11:8398-8402. (Pubitemid 41746953)
22. Fradet V, Lessard L, Begin LR, et al. Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res. 2004;10:8460-8464. (Pubitemid 40053410)
23. Gao K, Dai DL, Martinka M, et al. Prognostic significance of nuclear factor-κB p105/p50 in human melanoma and its role in cell migration. Cancer Res. 2006;66:8382-8388. (Pubitemid 44449148)
24. Jin X, Wang Z, Qiu L, et al. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci. 2008;99:582-589. (Pubitemid 351228577)
25. Weichert W, Boehm M, Gekeler V, et al. High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523-530. (Pubitemid 47258447)
26. Zlobec I, Terracciano L, Jass JR, et al. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch. 2007;451:763-769. (Pubitemid 47497938)
27. Cregger M, Berger AJ, Rimm DL. Immunohistochemical and quantitative analysis of protein expression. Arch Pathol Lab Med. 2006;130:1026-1030. (Pubitemid 44061434)
28. Critchley HO, Saunders PT. Hormone receptor dynamics in a receptive human endometrium. Reprod Sci. 2009;16:191-199.
29. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 2006;6:360-368.
30. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling cascades: I, membrane-associated signaling complexes. Trends Endocrinol Metab. 2002;13:349-354. (Pubitemid 36733951)
31. Seo KH, Lee HS, Jung B, et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation. Cancer Res. 2004;64:6482-6488. (Pubitemid 39297904)
32. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-930.
33. Acconcia F, Totta P, Ogawa S, et al. Survival versus apoptotic 17β-estradiol effect: role of ERα and ERβ activated non-genomic signaling. J Cell Physiol. 2005;203:193-201. (Pubitemid 40330938)
34. He YY, Cai B, Yang YX, et al. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009;100:1051-1061.
35. King AE, Collins F, Klonisch T, et al. An additive interaction between the NFκB and estrogen receptor signalling pathways in human endometrial epithelial cells. Hum Reprod. 2010;25:510-518.
36. Mizumoto Y, Kyo S, Kiyono T, et al. Activation of NF-κB is a novel target of KRAS-induced endometrial carcinogenesis. Clin Cancer Res. 2011;17:1341-1350.
37. Cicinelli E, Resta L, Nicoletti R, et al. Endometrial micropolyps at fluid hysteroscopy suggest the existence of chronic endometritis. Hum Reprod. 2005;20:1386-1389. (Pubitemid 40790268)
38. Erdemoglu E, Güney M, Karahan N, et al. Expression of cyclooxygenase-2, matrix metalloproteinase-2 and matrix metalloproteinase-9 in premenopausal and postmenopausal endometrial polyps. Maturitas. 2008;59:268-274.
39. Erkanli S, Bolat F, Kayaselcuk F, et al. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol. 2007;104:320-325. (Pubitemid 46135664)
40. Cao QJ, Einstein MH, Anderson PS, et al. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol. 2002;21:147-154. (Pubitemid 34260635)
41. Orejuela FJ, Ramondetta LM, Smith J, et al. Estrogen and progesterone receptors and cydooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005;97:483-488. (Pubitemid 40614893)
42. Ferrandina G, Legge F, Ranelletti FO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002; 95:801-807. (Pubitemid 34839672)
43. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cydooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192:1262-1271.
44. Lambropoulou M, Alexiadis G, Limberis V, et al. Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma. Histol Histopathol. 2005;20:753-759. (Pubitemid 40932593)
45. Jeon YT, Kang S, Kang DH, et al. Cydooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1538-1542. (Pubitemid 39202324)
46. Karnes WE, Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res. 1998;58:5473-5477. (Pubitemid 28551132)
47. Nieminen TT, Gylling A, Abdel-Rahman WM, et al. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res. 2009;15:5772-5783.
48. Rios SS, Andrade RV, Pereira RW, et al. Microsatellite instability in endometrial polyps. Eur J Obstet Gynecol Reprod Biol. 2010;153:193-197.
49. Wallace AE, Gibson DA, Saunders PT, et al. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010;206:141-157.
50. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256. (Pubitemid 33104278)
51. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981-986. (Pubitemid 29169731)